BioCryst Pharmaceuticals, Inc. (BCRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Core Insights - BioCryst is undergoing significant transformation and is positioned for exciting developments in the near future [1] Company Performance - The company reported substantial growth in new patient prescriptions for ORLADEYO in 2025, marking a pivotal year for BioCryst [2]